Press Release

REDWOOD CITY, Calif., May 31, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointments of Paul E. Cayer as Chief Financial Officer and Omega Therapeutics President and CEO, Mahesh Karande to the … Read more

Data demonstrated that a single oral dose of D-4517.2 significantly reduced choroidal neovascularization (CNV) lesions to a level comparable to D-4517.2 delivered subcutaneously and Aflibercept administered intravitreally at the same mass dose in a laser-induced CNV mouse model  Findings from a second preclinical study in a VLDLR−/− mouse model demonstrated oral and subcutaneous administration of … Read more

Data demonstrated D-4559 switches tumor associated macrophages from an M2 to M1 pro-inflammatory phenotype leading to reduction in tumor growth in a mouse model of hepatocellular carcinoma The data supports development of the potent macrophage switching drug as a potentially safe and effective agent that can be used systemically for the treatment of hepatocellular carcinoma … Read more

Preclinical data to be presented at AACR will showcase the potential effect of D-4559, a potent macrophage switching nanomedicine, on reducing tumor growth in a mouse model of hepatocellular carcinoma, a type of liver cancer Ashvattha will present preclinical data at ARVO on its oral formulation of D-4517.2, a potent anti-angiogenic nanomedicine, in a laser-induced … Read more

– The study will evaluate the safety, tolerability and ability of [18F]OP-801 to cross the blood brain barrier and selectively target neuroinflammation in individuals with ALS and healthy volunteers–   REDWOOD CITY, Calif., February 6, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel nanomedicines called hydroxyl dendrimer therapeutics (HDT), today announced that the … Read more

REDWOOD CITY, Calif., February 2, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a new class of precision medicines, today announced that the Company will provide a corporate overview at two upcoming investor conferences. The corporate overview will highlight the company’s innovative approach to precision nanomedicine … Read more

REDWOOD CITY, Calif., January 3, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a new class of precision medicines, today announced that the Company will provide a corporate overview at Biotech Showcase 2023 taking place in San Francisco, California, from January 9-11, 2023. Presenter Jeffrey Cleland, … Read more

REDWOOD CITY, Calif., October 20, 2022 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel hydroxyl dendrimer therapeutics (HDTs), today announced that Steve Maricich, M.D., Ph.D., joined the company as chief medical officer. Dr. Maricich joins Ashvattha as a seasoned clinical development physician and translational scientist with more than 15 years of industry and academic … Read more

– Data demonstrated [18F]OP-801 is a promising tracer for imaging activated macrophages/microglia with high sensitivity in the lumbar spine of a murine model of multiple sclerosis (MS) – – Treatment of MS model mice with a hydroxyl dendrimer CSF1R inhibitor demonstrated selective killing of reactive microglia and lower uptake of the investigative PET tracer compared … Read more

– Scientific collaborators at Stanford University will present data on an imaging and treatment regimen demonstrating the microglial targeting of [18F]OP-801 in a mouse model of multiple sclerosis and the synthesis of [18F]OP-801 for the ongoing clinical trial –   REDWOOD CITY, Calif., September 15, 2022 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel … Read more